Auron Therapeutics, Inc. — Form D/A
Auron Therapeutics, Inc. of NEWTON, MA, a company, filed a Form D amendment with the SEC on 2023-10-20. The offering totals $48.2M, of which $38.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-10-20
- Form: D/A
- Accession: 0001746139-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $48.2M
- Amount sold: $38.4M
- Remaining: $9.8M
- Investors: 10
- Date of first sale: 2022-07-14
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-454017
Issuer
- Name: Auron Therapeutics, Inc.
- CIK: 0001746139
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 55 CHAPEL STREET, NEWTON, MA, 02458
- Phone: 310-922-5881
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Eric Duncan Shiozaki | Director | Newton, MA |
| Christopher Duncan Guiffre | Executive Officer | Newton, MA |
| Briggs Duncan Morrison | Director | Newton, MA |
| Pini Duncan Orbach | Director | Newton, MA |
| Katharine Yen | Director | Newton, MA |
| Katharine Yen | Executive Officer | Newton, MA |
| Alexandra Cantley | Director | Newton, MA |
| Victoria Duncan Richon | Director | Newton, MA |
| Anna Duncan French | Director | Newton, MA |
| Serge Duncan Messerlian | Director | Newton, MA |
| Alon Duncan Lazarus | Director | Newton, MA |
| Isaac Ciechanover | Director | CAMBRIDGE, MA |
| John Duncan Higgons | Director | Wellesley, MA |
Other filings by this issuer (5)
More